For patients with chronic, limb-threatening ischemia due to atherosclerosis that affects the arteries below the knee, a revascularization strategy using endovascular treatment as the first option was ...

Atherectomy for Lower Limb Revascularization: A Systematic Review and Meta-Analysis, published in the Journal of Endovascular Therapy, demonstrated that atherectomy followed by drug-coated balloon ...

A new technique known as targeted muscle reinnervation (TMR), where severed nerves in the amputated limb are rerouted to other muscle targets, is showing impressive reductions in debilitating phantom ...

FOR more than ten years there has been a tendency to use below-the-knee rather than supracondylar amputation at the New England Deaconess Hospital in the management of diabetic gangrene when more ...

Three new studies from Hospital for Special Surgery (HSS) highlight the use and advantages of osseointegration (OI) for ...

SURGICAL opinion varies widely as to the advisability of performing below-knee amputations in limbs that exhibit diminished circulation at the level of amputation. It has been shown that below-knee ...

A new surgical technique for below-the-knee amputations retains a person’s ability to receive sensory feedback from remaining muscles. Having a prosthetic leg driven by an amputee’s own nervous system ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Cordis Corporation is pleased to announce the launch of SLEEK® OTW Catheter, a new .014” Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter designed to ...

A new study, led by researchers from the University of Sheffield and published in BJS Open, highlights the urgent need to improve care and prevention strategies, especially for people with diabetes.

Researchers have invented a new neural interface and communication paradigm that is able to send movement commands from the central nervous system to a robotic prosthesis, and relay proprioceptive ...

LAS VEGAS, NV—The diversion of blood flow through arterialization of the deep veins in the foot holds up well at 2 years as a therapy for “no-option” patients with chronic limb-threatening ischemia ...